New combo therapy aims to zap remaining lung cancer spots
NCT ID NCT07379476
First seen Jan 31, 2026 · Last updated May 14, 2026 · Updated 20 times
Summary
This study tests whether adding local ablative therapy (like radiation) to the drug osimertinib can better control advanced EGFR-mutant lung cancer. About 64 adults with 3 or fewer remaining active tumor sites after initial drug treatment will be randomly assigned to continue osimertinib alone or with the added therapy. The goal is to see if the combination delays cancer progression longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Clinical Oncology, Prince of Wales Hospital
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.